FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need, today announced the pricing of senior unsecured notes in an aggregate principal amount of $1 billion, in an underwritten, registered public offering. The notes will mature on April 1, 2021, and will bear interest at an annual rate of 4.5 percent. The offering is expected to close March 30, 2011, subject to customary closing conditions.
